Rottenstein Law Group,LLP

Second Ethicon Vaginal Mesh Bellwether Case Ends in $3.27 Million Win for Plaintiff, Rottenstein Law Group LLP Notes

LogoThe second federal bellwether trial involving a vaginal mesh product manufactured by Johnson & Johnson subsidiary Ethicon has concluded, with the jury in the case finding in favor of plaintiff Jo Huskey and awarding her $3.27 million in damages, according to a September 5 Reuters report.* The trial of Huskey v. Ethicon (No. 12-5201; U.S. District Court for the Southern District of West Virginia) began on August 14 and ended after nearly two weeks. According to the Reuters report, “jurors found Ethicon liable for selling faulty devices and failing to warn patients and their doctors that users were at risk from side effects that include pain, bleeding and infection.”

Bayer Aims to Expand Xarelto Use Despite Known Risks, Rottenstein Law Group LLP Notes with Concern

LogoAccording to a Reuters report, Xarelto manufacturer Bayer is going to be testing the drug—currently very popular as a treatment for preventing strokes—on patients with “embolic stroke of undetermined source and peripheral artery disease” and for long-term prevention in patients who have suffered an acute coronary syndrome.”*

Next Ethicon Vaginal Mesh Bellwether Cases Moving Closer to Trials, Rottenstein Law Group LLP Notes

LogoThe Rottenstein Law Group LLP, a New York-based personal injury law firm representing plaintiffs nationwide in lawsuits against Ethicon, the manufacturer of GYNECARE PROLIFT vaginal mesh devices (http://gynecareproliftmeshlawsuit.net), which have allegedly caused serious injuries to women who were implanted with the devices as treatments for pelvic organ prolapse (POP) and stress urinary incontinence (SUI), is encouraged by the latest order issued by the federal court handling early trials involving the products.

Denial of Dismissal Motions Allows Bellwether Federal DePuy Pinnacle Trials to Begin, the Rottenstein Law Group LLP Reports

LogoThe Rottenstein Law Group LLP is currently representing plaintiffs with claims stemming from injuries allegedly caused by metal-on-metal DePuy Pinnacle hip replacement devices. United States District Judge Ed Kinkeade, who is overseeing several lawsuits involving the DePuy Orthopaedics Pinnacle hip implant system (In re: DePuy Orthopaedics, Inc. Pinnacle Hip Implant Products Liability Litigation; United States District Court for the Northern District of Texas, Dallas Division, No. 3:11-MD-2244-K) issued two memorandum opinions on July 18 denying motions of defendant DePuy, making it possible for two individual cases against the company and its parent, Johnson & Johnson, to proceed to trial. (Lay v. DePuy Orthopaedics, Inc., et al., No. 3:11-cv-03590-K; Herlihy-Paoli v. DePuy § Orthopaedics, Inc., et al. No 3:12-cv-04975-K.)

Rottenstein Law Group LLP Notes Rise in Number of Reported Alleged Injuries Prompting Xarelto Lawsuits

LogoIn 2013, the U.S. FDA received several hundred adverse event reports submitted by individuals who claimed to have a serious adverse side effect while taking Xarelto (rivaroxaban) (http://www.xareltoinjuryfirm.com), as compared to a lower number for Pradaxa (dabigatran).* Data show that the number of persons being prescribed these blood thinning drugs is estimated at about 4 million for the year, with Xarelto prescriptions outnumbering Pradaxa prescriptions by two-to-one.* Anticoagulants (or “blood thinners”) are considered high-risk prescription drugs because they can cause excessive internal bleeding and other injuries in some patients.

Xarelto Lawsuits Information Website Launched by Rottenstein Law Group LLP

LogoThe new site, www.xareltoinjuryfirm.com, offers comprehensive information about the severe adverse side effects associated with Xarelto. Like similar so-called “blood thinners” (anticoagulants), Xarelto carries a risk of internal bleeding (hemorrhaging) side effects, according to the U.S. Food and Drug Administration (FDA). Xarelto’s internal bleeding side effects cannot be controlled or reversed by physicians, however, making the drug more dangerous than other, conventional anticoagulants, such as warfarin (Coumadin).

FDA Calls on Health Experts to Advise on Testosterone Products Amid Growing Reports of Adverse Reactions and Injury Lawsuits, Rottenstein Law Group LLP Reports

LogoIn light of the growing concern about the dangers of prescription testosterone products, the U.S. Food and Drug Administration (FDA) has tentatively scheduled a Joint Meeting of the Bone, Reproductive and Urologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee for September 17.* The published agenda states: “The committees will discuss the appropriate indicated population for testosterone replacement therapy and the potential for adverse cardiovascular outcomes associated with this use.” The Rottenstein Law Group, a national personal injury law firm, earlier this year launched a new website, at http://www.testosteroneinjuryfirm.com, dedicated to helping men get more information about the dangers of popular, but often unnecessary, testosterone treatments.

Transvaginal Mesh Lawsuits News: Oral Arguments in C.R. Bard Plaintiffs' Motion to Amend Pretrial Order to Take Place on July 9, the Rottenstein Law Group LLP Reports

LogoPending transvaginal mesh lawsuits that have been consolidated into a multidistrict litigation involving C.R. Bard (In re: C.R. Bard, Inc., Pelvic Repair Systems Products Liability Litigation – MDL No. 2187) continue to move through pretrial proceedings with the latest Order dated July 2, 2014 stating that the Court will hear oral arguments on a plaintiffs’ motion to amend a previous pretrial order (Stipulated Evidence Preservation Protocol for Potential Trial Selection Cases, Order No. 121), on Wednesday, July 9. The hearing will take place via telephone before a U.S. Magistrate Judge in the U.S. District Court for the Southern District of West Virginia, where the MDL is being overseen.

Rottenstein Law Group Notes Request for Physician Participation in Registry to Track Use of Risperdal and Other Atypical Antipsychotic Drugs by Pregnant Women

LogoThe Rottenstein Law Group LLP, a national personal injury law firm which maintains a Risperdal lawsuit informational web site at www.risperdallawsuit.us, notes the call for physician participation by researchers who are compiling a registry of the use of atypical antipsychotic medications like Risperdal by pregnant women. The researchers are attempting to establish a link between the drugs and birth defects, as the use of these medications by pregnant women is increasing.